Responses cited increasing workloads, shrinking autonomy, mounting interference from hospital administrators and insurance ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

As conferences expand and money esclates in college football, is there a saturation point where fans say enough is enough? Is ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

A Florida woman has gone viral after posting an emotional video in which she admits regretting her vote for Donald Trump — ...

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Meet Emanuel Colombini of Eccentrica Cars, whose Lamborghini Diablo restomod is an analogue supercar for the modern age ...

The Adelaide mom is met with sympathy, her husband with praise and both of them cop opinions that belong back in 1963. She’s ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.